NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
Q3 2024 vs. Q2 2024
How the institutions holding NeuroSense Therapeutics Ltd. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 7 | 7 | 0 |
| Shares | 1.67M | 225.4K | −1.45M (−86.5%) |
| Value | $1.87M | $285.9K | −$1.59M (−84.7%) |
New holders (3)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cantor Fitzgerald, L. P. | 79,492 | $101.0K | 0.01% |
| Citadel Advisors LLC | 34,280 | $43.5K | 0.00% |
| Commonwealth Equity Services, LLC | 12,625 | $16.0K | 0.00% |
Sold out (3)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Armistice Capital, LLC | 1,584,000 | $1.77M |
| Morgan Stanley | 1,500 | $1.68K |
| Qube Research & Technologies Ltd | 54 | $60 |